1. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
- Author
-
Richard A. Adegbola, Julie Chaumont, Aldiouma Diallo, Marc LaForce, Elisa Marchetti, Cheryl M. Elie, Yuxiao Tang, Prasad S. Kulkarni, Godwin Enwere, Brian D. Plikaytis, Simonetta Viviani, Sanjay Juvekar, Varsha Parulekar, Ray Borrow, Fatoumata Diallo, Siddhivinayak Hirve, Olubukola T. Idoko, Lionel Martellet, Milagritos D. Tapia, Bou Diarra, Fadima Cheick Haidara, Helen Findlow, Marie-Pierre Preziosi, Ashish Bavdekar, Adebayo Akinsola, George M. Carlone, and Samba O. Sow
- Subjects
Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,Blood Bactericidal Activity ,Time Factors ,Adolescent ,Population ,The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa ,India ,Enzyme-Linked Immunosorbent Assay ,Meningococcal Vaccines ,Meningococcal vaccine ,Polysaccharide Vaccine ,Young Adult ,Conjugate vaccine ,MenA conjugate vaccine ,Internal medicine ,medicine ,Animals ,Humans ,education ,antibody persistence ,Child ,education.field_of_study ,business.industry ,Complement System Proteins ,medicine.disease ,Antibodies, Bacterial ,Healthy Volunteers ,Vaccination ,African meningitis belt ,Infectious Diseases ,Serologic and Safety Studies of a Group a Meningococcal Conjugate Vaccine ,Child, Preschool ,Immunology ,Africa ,Female ,Rabbits ,business ,MenAfriVac ,Meningitis ,Follow-Up Studies - Abstract
Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY). Antibody persistence in Africa and in India was investigated. Methods. A total of 900 subjects aged 2–29 years were followed up for 4 years in Senegal, Mali, and The Gambia (study A). A total of 340 subjects aged 2–10 years were followed up for 1 year in India (study B). In study A, subjects were randomized in a 2:1 ratio, and in study B a 1:1 ratio to receive either PsA-TT or PsACWY. Immunogenicity was evaluated by measuring MenA serum bactericidal antibody (SBA) with rabbit complement and by a group A–specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay. Results. In both studies, substantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more marked in the PsACWY group. At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in the PsA-TT group, whereas a slight increasing trend, more pronounced among the youngest, was observed in the participants aged
- Published
- 2015